QuiaPEG Pharmaceuticals Holding AB - Asset Resilience Ratio

Latest as of March 2017: 14.02%

QuiaPEG Pharmaceuticals Holding AB (QUIA) has an Asset Resilience Ratio of 14.02% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr3.36 Million

≈ $361.83K USD Cash + Short-term Investments

Total Assets

Skr23.99 Million

≈ $2.58 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2010)

This chart shows how QuiaPEG Pharmaceuticals Holding AB's Asset Resilience Ratio has changed over time. Check QuiaPEG Pharmaceuticals Holding AB PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down QuiaPEG Pharmaceuticals Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is QuiaPEG Pharmaceuticals Holding AB worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr3.36 Million	14.02%
Total Liquid Assets	Skr3.36 Million	14.02%

Asset Resilience Insights

Moderate Liquidity: QuiaPEG Pharmaceuticals Holding AB has 14.02% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

QuiaPEG Pharmaceuticals Holding AB Industry Peers by Asset Resilience Ratio

Compare QuiaPEG Pharmaceuticals Holding AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Genfit S.A. PA:GNFT	Biotechnology	64.01%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	22.98%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for QuiaPEG Pharmaceuticals Holding AB (2010–2010)

The table below shows the annual Asset Resilience Ratio data for QuiaPEG Pharmaceuticals Holding AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2010-12-31	24.43%	Skr4.86 Million ≈ $522.48K	Skr19.88 Million ≈ $2.14 Million	--

pp = percentage points

About QuiaPEG Pharmaceuticals Holding AB

ST:QUIA Sweden Biotechnology

Market Cap

$141.00K

Skr1.31 Million SEK

Market Cap Rank

#31276 Global

#739 in Sweden

Share Price

Skr0.00

Change (1 day)

-16.67%

52-Week Range

Skr0.00 - Skr0.00

All Time High

Skr464.25